SCHEMBL4415666

SCHEMBL4415666

CC(C)(C)OC(=O)NCCNC(=O)CCCCCCCCCCCO

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.73
CYP3A4 P08684 1/20 0.49
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47
CA1 P00915 5/20 0.47
CA2 P00918 5/20 0.47
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
EPHX1 P07099 1/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
CAPN1 P07384 1/20 0.41
NAAA Q02083 1/20 0.41
DRD2 P14416 1/20 0.41
RECQL P46063 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7199968 0.95 TDP1 (0.76) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL31251932 0.95 TDP1 (0.81) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL29091668 0.94 TDP1 (0.73) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL31226174 0.90 TDP1 (0.63) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL31225932 0.90 TDP1 (0.63) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL5365248 0.89 TDP1 (0.81) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL25835454 0.89 TDP1 (0.61) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL4527640 0.89 TDP1 (0.66) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL7207224 0.88 TDP1 (0.69) TDP1CYP3A4MAOAMAOBMEN1
SCHEMBL28348827 0.87 TDP1 (0.54) TDP1CYP3A4MAOAMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1691845-A4 COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE BRISTOL MYERS SQUIBB PHARMA CO (US) 2009-02-25 EP disclosed
EP-1691845-A1 COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE Bristol-Myers Squibb Pharma Company (US) 2006-08-23 EP disclosed
US-20050106100-A1 Compounds containing matrix metalloproteinase substrates and methods of their use LANTHEUS MEDICAL IMAGING, INC. 2005-05-19 US disclosed
WO-2005023314-A1 COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050106100-A1 Compounds containing matrix metalloproteinase substrates and methods of their use MMP1, MMP10, MMP8 TDP1 777/4885CYP3A4 3770/4885MAOA 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.